Medtronic

Data demonstrate high procedural success and low paravalvular leak for Medtronic’s new Engager TAVI offering in late-breaking trials session at the European Association for Cardio-Thoracic Surgery annual meeting.

FDA clearance of Medtronic’s Affinity Pixie® Oxygenation system provides Perfusionists with options for a broader range of patients. The system was CE marked in May 2010 so won’t be new to Europeans.

New data, presented at TCT 2012 from the ADVANCE registry, confirms that mortality rates with transcatheter aortic-valve implantation (TAVI) using Medtronic’s CoreValve have dropped steadily since the devices’ earliest clinical trials.

New Data Presented at the 24th Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium Show Sustained Blood Pressure Reduction and Safety with Symplicity™ Renal Denervation System in Patients with Treatment-Resistant Hypertension

TAVI is a great case study in technology adoption, most strikingly pointing to post-market data in the form of registries as a window on real world use of a technique which actually makes for a pretty compelling endorsement of EU regulatory rules.

With a focus on developing lesion specific solutions for peripheral artery disease, Medtronic, Inc. has announced the U.S. and international launches of the Amphirion Plus Percutaneous Transluminal Angioplasty (PTA) Catheter for the interventional treatment of atherosclerotically narrowed or occluded leg arteries below the knee.

Medtronic’s new design multi-electrode radiofrequency renal denervation system builds on experience with the Symplicity™ Renal Denervation System.

Medtronic, Inc. and China Kanghui Holdings announced today that they have entered into a merger agreement whereby Medtronic will acquire Kanghui. The agreement calls for Medtronic to pay approximately $816 million in cash.

Medtronic announces CE mark for CoreValve® Evolut™, incorporating features designed for optimal fit. With the new 23mm iteration, Medtronic claims its CoreValve family treats the broadest range of patient valve sizes.

Medtronic, Inc. has announced CE Mark for its new Affinity Fusion® oxygenation system, opening the door to a European launch. The system, which oxygenates and removing carbon dioxide from blood during various open-heart surgical procedures, incorporates numerous innovations for claimed patient safety and ease of use.

In a strikingly heartwarming example of humanity charities already exist to coordinate the distribution of usable, explanted pacemakers from deceased Americans to less fortunate people in the developing world. A new study suggests this is a safe and viable practice, although the manufacturers disagree, citing concerns over reprocessing practices.

Medtronic, Inc. has announced findings from a health-economic analysis published online before print in The Journal of the American College of Cardiology that suggest the company’s Symplicity™ renal denervation system is a cost-effective treatment strategy for patients with treatment-resistant hypertension.

Medtronic, Inc. is announcing twin milestones for its CoreValve® clinical program on the long road to U.S. approval. First, it completed enrollment in its study of high risk patients in its U.S. Pivotal Trial, and then FDA gave it the nod to start a global trial in intermediate patients.

Renal Denervation is probably the biggest buzzphrase in new therapies right now, given the size of the problem it purports to address. Medtronic has seen more promising data published at ESC, suggesting patients treated with its Symplicity™ system benefit from sustained and meaningful BP reduction at 18 months

Medtronic’s Arctic Front Advance™ Cryoablation System now delivers cold therapy to a larger area more evenly, the company claiming that this will aid cardiologists in delivering cardiac ablation therapy.

Before we saw the numbers we were backing the line that it would be stents up, pacing and spine down, and so it came to pass. Medtronic’s numbers show the importance of emerging markets and contributions from its newly acquired businesses as the company posts 5% revenue gains.